S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
OTCMKTS:MYDP

Dougherty's Pharmacy (MYDP) Stock Forecast, Price & News

$0.02
0.00 (0.00%)
(As of 03/15/2021)
Add
Compare
Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.02
52-Week Range
$0.00
$0.02
Volume
9,000 shs
Average Volume
9,011 shs
Market Capitalization
$346.47 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive MYDP News and Ratings via Email

Sign-up to receive the latest news and ratings for Dougherty's Pharmacy and its competitors with MarketBeat's FREE daily newsletter.

About Dougherty's Pharmacy

Dougherty's Pharmacy, Inc. focuses on acquiring, managing, and growing community based pharmacies in the Southwest Region of the United States. Its flagship store is Dougherty's Pharmacy, a turn-key multi-service pharmacy located in Dallas, Texas. The company was formerly known as Ascendant Solutions, Inc. and changed its name to Dougherty's Pharmacy, Inc. in May 2017. Dougherty's Pharmacy, Inc. was founded in 1929 and is based in Dallas, Texas.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug stores & proprietary stores
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:MYDP
Employees
75
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$346.47 thousand
Optionable
Not Optionable

Company Calendar

Last Earnings
8/14/2018
Today
5/16/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.16 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Dougherty's Pharmacy (OTCMKTS:MYDP) Frequently Asked Questions

How were Dougherty's Pharmacy's earnings last quarter?

Dougherty's Pharmacy, Inc. (OTCMKTS:MYDP) issued its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm earned $9.17 million during the quarter.
View Dougherty's Pharmacy's earnings history
.

Who are Dougherty's Pharmacy's key executives?
Dougherty's Pharmacy's management team includes the following people:
  • Mr. James C. Leslie CPA, CPA, Chairman, Interim Pres & CFO (Age 66, Pay $100k)
  • Mr. Stewart I. Edington, Chief Exec. Officer (Age 52)
  • Ms. Katherine Burrow, Managing Director of Bus. Devel.
  • Ms. Susan K. Olson, Sec.
  • Ms. Robin Bruce, Controller
  • Mr. Rick Troberman, Exec. VP of Sales and Marketing
What other stocks do shareholders of Dougherty's Pharmacy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dougherty's Pharmacy investors own include Zynerba Pharmaceuticals (ZYNE), Armstrong World Industries (AWI), Bristol-Myers Squibb (BMY), National Vision (EYE), Floor & Decor (FND), Toronto-Dominion Bank (TD), Atlassian (TEAM), Altice USA (ATUS), Amneal Pharmaceuticals (AMRX) and (AMR).

What is Dougherty's Pharmacy's stock symbol?

Dougherty's Pharmacy trades on the OTCMKTS under the ticker symbol "MYDP."

How do I buy shares of Dougherty's Pharmacy?

Shares of MYDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dougherty's Pharmacy's stock price today?

One share of MYDP stock can currently be purchased for approximately $0.02.

How much money does Dougherty's Pharmacy make?

Dougherty's Pharmacy has a market capitalization of $346.47 thousand.

How many employees does Dougherty's Pharmacy have?

Dougherty's Pharmacy employs 75 workers across the globe.

What is Dougherty's Pharmacy's official website?

The official website for Dougherty's Pharmacy is www.doughertys.com.

How can I contact Dougherty's Pharmacy?

Dougherty's Pharmacy's mailing address is 5924 ROYAL LANE SUITE 250, DALLAS TX, 75230. The company can be reached via phone at 972-250-0945, via email at [email protected], or via fax at 972-250-0934.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.